Good communication again on the second asset out of U Penn which has plenty of firepower pre-clinically to compliment CHM-1101. They certainly didn't mess around in getting the manufacturing done so soon after licensing. Looks like CDH17 will also have the same urgency to market, yet astute attention to detail as CLTX. So glad we have one out of U Penn the godfather of Car-t / Cell therapy.
Notice the addition in the introduction (may have missed it in other comms) - "the ASX leader in cell therapy" Can't wait to see what other assets are added to build this company into a world class Cell therapy company (due to be announced this year).
11th November is rolling in quickly...
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)